Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment

Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment is a phase 3, randomised interventional study registered as NCT07160686 by University of Birmingham, with a registry enrolment figure of 1456 participants, started 2026-03-02 and due to reach its primary completion in 2029-09-30. Interventions recorded: Apixaban; Placebo. Conditions listed: Thromboprophylaxis. Primary outcome: 18.3.1.1 Objectively confirmed VTE. Lung eligibility wording from the registry: "* Newly diagnosed locally advanced or metastatic primary lung cancer (histologically/ cytologically confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT". Sites: United Kingdom. United Kingdom sites listed: 1. No results are recorded here; the registry entry is the source.